

WASHINGTON

perspectives

An Analysis and Commentary on Federal Health Care Issues by Larry Goldberg

August 1, 2018

CMS Issues Final Inpatient Rehabilitation Facility FY 2019 PPS Update



The Centers for Medicare and Medicaid Services (CMS) have published a final rule to update the payment rates for inpatient rehabilitation facilities (IRFs) for Federal fiscal year (FY) 2019, (that is, for discharges occurring on or after October 1, 2018, and on or before September 30, 2019)

The 212-page document is scheduled for publication in the **Federal Register** on August 6th. A copy is currently available at: https://s3.amazonaws.com/public-inspection.federalregister.gov/2018-16517.pdf. This link will change upon publication.

Comment

CMS says that the overall economic impact of this final rule results in an estimated \$105 million increase in FY 2019 IRF PPS payments.

Further, CMS estimates a \$10.5 million reduction in costs in FY 2020 as a result of the removal of the FIM™ instrument and associated Function Modifiers from the IRF-PAI. CMS says a total reduction of \$20.5 million in costs in FY 2019 results from the removal of certain IRF coverage requirements. Finally, CMS says a reduction of \$2.5 million in FY 2019 results from new quality reporting requirements.

This is a well-developed and organized rule. CMS has provided clear final decision sections.

Page numbers in red pertain to the material in the display copy.

FY 2019 Market Basket Update and Productivity Adjustment (Page 42)

CMS is finalizing that the market basket increase factor for FY 2019 will be 2.9 percent. This amount is reduced further by mandates of the **Affordable Care Act** (ACA); that is, reductions for productivity estimated at -0.8 percent and another reduction amount of -0.75 percent. Therefore, the final increase will be 1.35 percent.

Labor-Related Share for FY 2019 (Page 45)

The FY 2019 labor-related share is **70.5** percent. By comparison, the current FY 2018 labor-related share is 70.7 percent.



Wage Adjustment for FY 2019 (Page 47)

For FY 2019, CMS proposes to continue using OMB delineations to calculate the area wage indexes.

The wage index applicable to FY 2019 is available on the CMS website at: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/InpatientRehabFacPPS/Data-Files.html. Table A is for urban areas, and Table B is for rural areas.

Facility Level Adjustment Factors (Page 38)

CMS currently adjust the prospective payment amount associated with a Case-Mix Group to account for facility-level characteristics such as an IRF's LIP, teaching status, and location in a rural area, if applicable, as described in §412.624(e). CMS is not making any changes to these factors for FY 2019.

FY 2019 Update to the Case-Mix Group (CMG) Relative Weights and Average Length of Stay Values (Page 26)

The table below contains the CMGs, the comorbidity tiers, the corresponding relative weights, and the average length of stay values for each CMG and tier for FY 2019. The average length of stay for each CMG is used to determine when an IRF discharge meets the definition of a short-stay transfer, which results in a per diem case level adjustment.

Relative Weights and Average Length of Stay Values for Case-Mix Groups

| CMG | CMG Description (M=motor, C=cognitive, A=age) | | Relative Weight | | | Average Length of Stay | | | |
|------|--|--------|-----------------|--------|-----------------------------|------------------------|--------|--------|-----------------------------|
| | | Tier 1 | Tier 2 | Tier 3 | No Comorbidities Tier | Tier 1 | Tier 2 | Tier 3 | No Comorbidities Tier |
| 0101 | Stroke M>51.05 | 0.8465 | 0.7365 | 0.6747 | 0.6451 | 8 | 11 | 9 | 8 |
| 0102 | Stroke M>44.45 and M<51.05 and C>18.5 | 1.0706 | 0.9315 | 0.8533 | 0.8159 | 11 | 12 | 10 | 10 |
| 0103 | Stroke M>44.45 and M<51.05 and C<18.5 | 1.2391 | 1.0781 | 0.9876 | 0.9443 | 12 | 13 | 11 | 12 |
| 0104 | Stroke M>38.85 and M<44.45 | 1.2938 | 1.1257 | 1.0312 | 0.9860 | 12 | 13 | 12 | 12 |
| 0105 | Stroke M>34.25 and M<38.85 | 1.4871 | 1.2938 | 1.1852 | 1.1333 | 14 | 14 | 14 | 13 |
| 0106 | Stroke M>30.05 and M<34.25 | 1.6628 | 1.4467 | 1.3253 | 1.2673 | 16 | 16 | 15 | 15 |



| CMG | CMG Description (M=motor, C=cognitive, A=age) | | Relative Weight | | | | Average Length of Stay | | | |
|------|---|--------|-----------------|--------|-----------------------------|--------|------------------------|--------|-----------------------------|--|
| | | Tier 1 | Tier 2 | Tier 3 | No Comorbidities Tier | Tier 1 | Tier 2 | Tier 3 | No Comorbidities Tier | |
| 0107 | Stroke M>26.15 and M<30.05 | 1.8653 | 1.6229 | 1.4867 | 1.4216 | 18 | 18 | 16 | 16 | |
| 0108 | Stroke M<26.15 and A>84.5 | 2.3056 | 2.0060 | 1.8376 | 1.7572 | 22 | 21 | 20 | 20 | |
| 0109 | Stroke M>22.35 and M<26.15 and A<84.5 | 2.0857 | 1.8147 | 1.6624 | 1.5896 | 19 | 19 | 18 | 18 | |
| 0110 | Stroke M<22.35 and A<84.5 | 2.7655 | 2.4060 | 2.2041 | 2.1076 | 26 | 26 | 23 | 23 | |
| 0201 | Traumatic brain injury M>53.35 and C>23.5 | 0.8235 | 0.6628 | 0.5922 | 0.5527 | 9 | 9 | 8 | 7 | |
| 0202 | Traumatic brain injury M>44.25 and M<53.35 and C>23.5 | 1.1508 | 0.9263 | 0.8275 | 0.7724 | 10 | 11 | 10 | 10 | |
| 0203 | Traumatic brain injury M>44.25 and C<23.5 | 1.2723 | 1.0240 | 0.9149 | 0.8539 | 13 | 13 | 11 | 10 | |
| 0204 | Traumatic brain injury M>40.65 and M<44.25 | 1.3841 | 1.1141 | 0.9953 | 0.9290 | 13 | 13 | 11 | 11 | |
| 0205 | Traumatic brain injury M>28.75 and M<40.65 | 1.6330 | 1.3143 | 1.1743 | 1.0960 | 14 | 15 | 13 | 13 | |
| 0206 | Traumatic brain injury M>22.05 and M<28.75 | 1.9661 | 1.5825 | 1.4139 | 1.3196 | 18 | 18 | 15 | 15 | |
| 0207 | Traumatic brain injury M<22.05 | 2.4863 | 2.0012 | 1.7879 | 1.6687 | 30 | 22 | 19 | 18 | |
| 0301 | Non- traumatic brain injury M>41.05 | 1.1727 | 0.9483 | 0.8703 | 0.8135 | 11 | 11 | 10 | 10 | |



| СМС | CMG Description (M=motor, C=cognitive, A=age) | Relative Weight | | | | Average Length of Stay | | | |
|------|---|-----------------|--------|--------|-----------------------------|------------------------|--------|--------|-----------------------------|
| | A-age) | Tier 1 | Tier 2 | Tier 3 | No Comorbidities Tier | Tier 1 | Tier 2 | Tier 3 | No Comorbidities Tier |
| 0302 | Non- traumatic brain injury M>35.05 and M<41.05 | 1.4347 | 1.1603 | 1.0648 | 0.9953 | 12 | 13 | 12 | 12 |
| 0303 | Non- traumatic brain injury M>26.15 and M<35.05 | 1.6572 | 1.3402 | 1.2300 | 1.1496 | 15 | 14 | 13 | 13 |
| 0304 | Non- traumatic brain injury M<26.15 | 2.1203 | 1.7147 | 1.5737 | 1.4709 | 20 | 19 | 16 | 16 |
| 0401 | Traumatic spinal cord injury M>48.45 | 1.0040 | 0.8097 | 0.7490 | 0.6855 | 10 | 10 | 9 | 9 |
| 0402 | Traumatic spinal cord injury M>30.35 and M<48.45 | 1.4873 | 1.1996 | 1.1096 | 1.0155 | 14 | 13 | 13 | 12 |
| 0403 | Traumatic spinal cord injury M>16.05 and M<30.35 | 2.3688 | 1.9105 | 1.7673 | 1.6175 | 25 | 22 | 19 | 18 |
| 0404 | Traumatic spinal cord injury M<16.05 and A>63.5 | 4.0377 | 3.2566 | 3.0125 | 2.7571 | 45 | 36 | 31 | 30 |
| 0405 | Traumatic spinal cord injury M<16.05 and A<63.5 | 3.6175 | 2.9177 | 2.6989 | 2.4701 | 26 | 35 | 29 | 26 |
| 0501 | Non- traumatic spinal cord injury M>51.35 | 0.9171 | 0.7145 | 0.6605 | 0.6070 | 9 | 10 | 8 | 8 |
| 0502 | Non- traumatic spinal cord injury M>40.15 and M<51.35 | 1.2182 | 0.9491 | 0.8774 | 0.8063 | 11 | 11 | 10 | 10 |
| 0503 | Non- traumatic spinal cord injury M>31.25 and M<40.15 | 1.5156 | 1.1809 | 1.0916 | 1.0031 | 14 | 13 | 12 | 12 |



| СМС | CMG Description (M=motor, C=cognitive, A=age) | | Relative Weight | | | | Average Length of Stay | | | |
|------|---|--------|-----------------|--------|-----------------------------|--------|------------------------|--------|-----------------------------|--|
| | | Tier 1 | Tier 2 | Tier 3 | No Comorbidities Tier | Tier 1 | Tier 2 | Tier 3 | No Comorbidities Tier | |
| 0504 | Non- traumatic spinal cord injury M>29.25 and M<31.25 | 1.7426 | 1.3577 | 1.2551 | 1.1533 | 16 | 14 | 14 | 13 | |
| 0505 | Non- traumatic spinal cord injury M>23.75 and M<29.25 | 1.9957 | 1.5550 | 1.4374 | 1.3209 | 18 | 17 | 16 | 15 | |
| 0506 | Non- traumatic spinal cord injury M<23.75 | 2.6996 | 2.1034 | 1.9443 | 1.7867 | 26 | 23 | 21 | 20 | |
| 0601 | Neurological M>47.75 | 1.0736 | 0.8242 | 0.7624 | 0.6948 | 9 | 9 | 9 | 8 | |
| 0602 | Neurological M>37.35 and M<47.75 | 1.3920 | 1.0686 | 0.9884 | 0.9008 | 12 | 12 | 11 | 10 | |
| 0603 | Neurological M>25.85 and M<37.35 | 1.7124 | 1.3146 | 1.2159 | 1.1082 | 14 | 14 | 13 | 13 | |
| 0604 | Neurological M<25.85 | 2.2148 | 1.7003 | 1.5727 | 1.4334 | 19 | 17 | 16 | 16 | |
| 0701 | Fracture of lower extremity M>42.15 | 1.0280 | 0.8387 | 0.7948 | 0.7171 | 10 | 10 | 9 | 9 | |
| 0702 | Fracture of lower extremity M>34.15 and M<42.15 | 1.3083 | 1.0674 | 1.0115 | 0.9127 | 12 | 12 | 12 | 11 | |
| 0703 | Fracture of lower extremity M>28.15 and M<34.15 | 1.5600 | 1.2728 | 1.2062 | 1.0883 | 14 | 14 | 14 | 13 | |
| 0704 | Fracture of lower extremity M<28.15 | 1.9907 | 1.6242 | 1.5392 | 1.3888 | 18 | 18 | 17 | 16 | |
| 0801 | Replacement of lower extremity joint M>49.55 | 0.8391 | 0.6841 | 0.6185 | 0.5754 | 8 | 8 | 8 | 7 | |



| CMG | CMG Description (M=motor, C=cognitive, A=age) | | Relative Weight | | | | Average Length of Stay | | | |
|------|--|--------|-----------------|--------|-----------------------------|--------|------------------------|--------|-----------------------------|--|
| | | Tier 1 | Tier 2 | Tier 3 | No Comorbidities Tier | Tier 1 | Tier 2 | Tier 3 | No Comorbidities Tier | |
| 0802 | Replacement of lower extremity joint M>37.05 and M<49.55 | 1.0766 | 0.8777 | 0.7936 | 0.7382 | 11 | 9 | 9 | 9 | |
| 0803 | Replacement of lower extremity joint M>28.65 and M<37.05 and A>83.5 | 1.4123 | 1.1514 | 1.0410 | 0.9684 | 13 | 13 | 12 | 11 | |
| 0804 | Replacement of lower extremity joint M>28.65 and M<37.05 and A<83.5 | 1.2727 | 1.0376 | 0.9381 | 0.8727 | 12 | 12 | 11 | 10 | |
| 0805 | Replacement of lower extremity joint M>22.05 and M<28.65 | 1.5169 | 1.2367 | 1.1181 | 1.0401 | 14 | 14 | 12 | 12 | |
| 0806 | Replacement of lower extremity joint M<22.05 | 1.8691 | 1.5238 | 1.3777 | 1.2816 | 17 | 17 | 15 | 14 | |
| 0901 | Other orthopedic M>44.75 | 1.0283 | 0.8073 | 0.7481 | 0.6894 | 11 | 10 | 9 | 8 | |
| 0902 | Other orthopedic M>34.35 and M<44.75 | 1.3030 | 1.0230 | 0.9479 | 0.8736 | 12 | 12 | 11 | 10 | |
| 0903 | Other orthopedic M>24.15 and M<34.35 | 1.6262 | 1.2768 | 1.1831 | 1.0903 | 14 | 14 | 13 | 12 | |
| 0904 | Other orthopedic M<24.15 | 2.0372 | 1.5995 | 1.4821 | 1.3659 | 17 | 17 | 16 | 15 | |
| 1001 | Amputation, lower extremity M>47.65 | 1.0941 | 0.9260 | 0.8226 | 0.7584 | 11 | 11 | 10 | 9 | |



| CMG | CMG Description (M=motor, C=cognitive, A=age) | | Relati | ive Weight | | Average Length of Stay | | | |
|------|---|--------|--------|------------|-----------------------------|------------------------|--------|--------|-----------------------------|
| | A-age) | Tier 1 | Tier 2 | Tier 3 | No Comorbidities Tier | Tier 1 | Tier 2 | Tier 3 | No Comorbidities Tier |
| 1002 | Amputation, lower extremity M>36.25 and M<47.65 | 1.3984 | 1.1835 | 1.0513 | 0.9693 | 13 | 13 | 12 | 12 |
| 1003 | Amputation, lower extremity M<36.25 | 2.0247 | 1.7136 | 1.5222 | 1.4034 | 18 | 18 | 16 | 15 |
| 1101 | Amputation, non-lower extremity M>36.35 | 1.3618 | 1.0044 | 1.0044 | 0.8832 | 12 | 11 | 11 | 11 |
| 1102 | Amputation, non-lower extremity M<36.35 | 1.9208 | 1.4167 | 1.4167 | 1.2458 | 17 | 15 | 15 | 13 |
| 1201 | Osteoarthritis M>37.65 | 1.1125 | 0.9541 | 0.8710 | 0.7877 | 11 | 10 | 10 | 9 |
| 1202 | Osteoarthritis M>30.75 and M<37.65 | 1.4092 | 1.2085 | 1.1032 | 0.9978 | 13 | 13 | 12 | 12 |
| 1203 | Osteoarthritis M<30.75 | 1.7067 | 1.4637 | 1.3361 | 1.2084 | 15 | 16 | 15 | 14 |
| 1301 | Rheumatoid, other arthritis M>36.35 | 1.0977 | 0.9523 | 0.8893 | 0.8342 | 10 | 10 | 10 | 10 |
| 1302 | Rheumatoid, other arthritis M>26.15 and M<36.35 | 1.4355 | 1.2454 | 1.1630 | 1.0909 | 12 | 13 | 13 | 12 |
| 1303 | Rheumatoid, other arthritis M<26.15 | 1.7337 | 1.5041 | 1.4046 | 1.3175 | 14 | 17 | 15 | 15 |
| 1401 | Cardiac M>48.85 | 0.9226 | 0.7511 | 0.6772 | 0.6103 | 9 | 8 | 8 | 7 |
| 1402 | Cardiac M>38.55 and M<48.85 | 1.2379 | 1.0079 | 0.9086 | 0.8189 | 11 | 11 | 10 | 10 |
| 1403 | Cardiac M>31.15 and M<38.55 | 1.4752 | 1.2011 | 1.0828 | 0.9759 | 13 | 13 | 12 | 11 |
| 1404 | Cardiac M<31.15 | 1.8581 | 1.5129 | 1.3639 | 1.2292 | 17 | 16 | 15 | 13 |



| CMG | CMG Description (M=motor, C=cognitive, A=age) | | Relative Weight | | | | Average Length of Stay | | | |
|------|---|--------|-----------------|--------|-----------------------------|--------|------------------------|--------|-----------------------------|--|
| | | Tier 1 | Tier 2 | Tier 3 | No Comorbidities Tier | Tier 1 | Tier 2 | Tier 3 | No Comorbidities Tier | |
| 1501 | Pulmonary M>49.25 | 1.0145 | 0.8753 | 0.7927 | 0.7596 | 9 | 10 | 9 | 8 | |
| 1502 | Pulmonary M>39.05 and M<49.25 | 1.2970 | 1.1191 | 1.0134 | 0.9711 | 11 | 11 | 10 | 11 | |
| 1503 | Pulmonary M>29.15 and M<39.05 | 1.5391 | 1.3280 | 1.2026 | 1.1524 | 14 | 13 | 12 | 12 | |
| 1504 | Pulmonary M<29.15 | 1.9395 | 1.6735 | 1.5155 | 1.4522 | 19 | 16 | 15 | 14 | |
| 1601 | Pain syndrome M>37.15 | 1.2123 | 0.9280 | 0.8814 | 0.7954 | 9 | 11 | 10 | 10 | |
| 1602 | Pain syndrome M>26.75 and M<37.15 | 1.5361 | 1.1758 | 1.1169 | 1.0079 | 11 | 12 | 12 | 12 | |
| 1603 | Pain syndrome M<26.75 | 1.8637 | 1.4266 | 1.3551 | 1.2228 | 12 | 16 | 15 | 14 | |
| 1701 | Major multiple trauma without brain or spinal cord injury M>39.25 | 1.2825 | 0.9724 | 0.9103 | 0.8196 | 14 | 11 | 10 | 10 | |
| 1702 | Major multiple trauma without brain or spinal cord injury M>31.05 and M<39.25 | 1.5510 | 1.1760 | 1.1009 | 0.9912 | 14 | 14 | 12 | 11 | |
| 1703 | Major multiple trauma without brain or spinal cord Injury M>25.55 and M<31.05 | 1.8097 | 1.3722 | 1.2846 | 1.1565 | 15 | 15 | 14 | 13 | |
| 1704 | Major multiple trauma without brain or spinal cord injury M<25.55 | 2.3097 | 1.7513 | 1.6395 | 1.4761 | 20 | 19 | 17 | 16 | |



| CMG | CMG Description (M=motor, C=cognitive, A=age) | | Relati | ive Weight | | Average Length of Stay | | | |
|------|--|--------|--------|------------|-----------------------------|------------------------|--------|--------|-----------------------------|
| | | Tier 1 | Tier 2 | Tier 3 | No Comorbidities Tier | Tier 1 | Tier 2 | Tier 3 | No Comorbidities Tier |
| 1801 | Major multiple trauma with brain or spinal cord injury M>40.85 | 1.1285 | 1.0063 | 0.8504 | 0.7943 | 12 | 11 | 10 | 10 |
| 1802 | Major multiple trauma with brain or spinal cord injury M>23.05 and | 1.6639 | 1.4838 | 1.2539 | 1.1712 | 16 | 17 | 14 | 13 |
| | M<40.85 | | | | | | | | |
| 1803 | Major multiple trauma with brain or spinal cord injury | 2.6145 | 2.3315 | 1.9703 | 1.8403 | 30 | 25 | 20 | 19 |
| | M<23.05 | | | | | | | | |
| 1901 | Guillain Barre M>35.95 | 1.4000 | 1.0049 | 0.9440 | 0.9096 | 15 | 13 | 11 | 11 |
| 1902 | Guillain Barre M>18.05 and M<35.95 | 2.4651 | 1.7694 | 1.6622 | 1.6017 | 24 | 21 | 18 | 18 |
| 1903 | Guillain Barre M<18.05 | 4.2669 | 3.0627 | 2.8772 | 2.7725 | 46 | 31 | 30 | 30 |
| 2001 | Miscellaneous M>49.15 | 0.9693 | 0.7709 | 0.7160 | 0.6500 | 9 | 9 | 8 | 8 |
| 2002 | Miscellaneous M>38.75 and M<49.15 | 1.2597 | 1.0018 | 0.9306 | 0.8448 | 12 | 11 | 10 | 10 |
| 2003 | Miscellaneous M>27.85 and M<38.75 | 1.5484 | 1.2314 | 1.1438 | 1.0384 | 14 | 14 | 12 | 12 |
| 2004 | Miscellaneous M<27.85 | 1.9734 | 1.5695 | 1.4578 | 1.3234 | 18 | 17 | 15 | 15 |
| 2101 | Burns M>0 | 1.9075 | 1.5493 | 1.4963 | 1.3168 | 22 | 16 | 16 | 14 |
| 5001 | Short-stay cases, length of stay is 3 days or fewer | | | | 0.1599 | | | | 2 |
| 5101 | Expired, orthopedic, length of stay is 13 days or fewer | | | | 0.7539 | | | | 8 |



| CMG | CMG Description (M=motor, C=cognitive, A=age) | | Relative Weight | | | | Average Length of Stay | | | |
|------|---|--------|-----------------|--------|-----------------------------|--------|------------------------|--------|-----------------------------|--|
| | | Tier 1 | Tier 2 | Tier 3 | No Comorbidities Tier | Tier 1 | Tier 2 | Tier 3 | No Comorbidities Tier | |
| 5102 | Expired, orthopedic, length of stay is 14 days or more | | | | 1.6493 | | | | 18 | |
| 5103 | Expired, not orthopedic, length of stay is 15 days or fewer | | | | 0.8091 | | | | 8 | |
| 5104 | Expired, not orthopedic, length of stay is 16 days or more | | | | 2.1145 | | | | 21 | |

Description of the IRF Standard Payment Conversion Factor and Payment Rates for FY 2019

Calculations to Determine the FY 2019 Standard Payment Conversion Factor (Page 56)

| Explanation for Adjustment | Calculations | |
|---|--------------|----------|
| Standard Payment Conversion Factor for FY 2018 | | \$15,838 |
| Market Basket Increase Factor for FY 2019 (2.9 percent), reduced by 0.8 percentage point for the productivity adjustment as required by section $1886(j)(3)(C)(ii)(I)$ of the Act, and reduced by 0.75 percentage point in accordance with sections $1886(j)(3)(C)(ii)(II)$ and $1886(j)(3)(D)(v)$ of the Act | х | 1.0135 |
| Budget Neutrality Factor for the Wage Index and Labor-Related Share | х | 1.0000 |
| Budget Neutrality Factor for the Revisions to the CMG Relative Weights | х | 0.9981 |
| FY 2019 Standard Payment Conversion Factor | = | \$16,021 |

The CMG relative weights (shown above) are multiplied the FY 2019 standard payment conversion factor (\$16,021), resulting in unadjusted IRF prospective payment rates for FY 2019 as shown below.

FY 2019 Payment Rates (Page 57)

| СМС | Payment Rate Tier 1 | Payment Rate Tier 2 | Payment Rate Tier 3 | Payment Rate No Comorbidity |
|------|---------------------|---------------------|---------------------|--------------------------------|
| 0101 | \$ 13,561.78 | \$ 11,799.47 | \$ 10,809.37 | \$ 10,335.15 |
| 0102 | \$ 17,152.08 | \$ 14,923.56 | \$ 13,670.72 | \$ 13,071.53 |
| 0103 | \$ 19,851.62 | \$ 17,272.24 | \$ 15,822.34 | \$ 15,128.63 |
| 0104 | \$ 20,727.97 | \$ 18,034.84 | \$ 16,520.86 | \$ 15,796.71 |
| 0105 | \$ 23,824.83 | \$ 20,727.97 | \$ 18,988.09 | \$ 18,156.60 |
| 0106 | \$ 26,639.72 | \$ 23,177.58 | \$ 21,232.63 | \$ 20,303.41 |
| 0107 | \$ 29,883.97 | \$ 26,000.48 | \$ 23,818.42 | \$ 22,775.45 |
| 0108 | \$ 36,938.02 | \$ 32,138.13 | \$ 29,440.19 | \$ 28,152.10 |
| 0109 | \$ 33,415.00 | \$ 29,073.31 | \$ 26,633.31 | \$ 25,466.98 |
| 0110 | \$ 44,306.08 | \$ 38,546.53 | \$ 35,311.89 | \$ 33,765.86 |

WASHINGTON perspectives

| CMG | Payment Rate Tier 1 | Payment Rate Tier 2 | Payment Rate Tier 3 | Payment Rate No Comorbidity |
|------|---------------------|---------------------|---------------------|--------------------------------|
| 0201 | \$ 13,193.29 | \$ 10,618.72 | \$ 9,487.64 | \$ 8,854.81 |
| 0202 | \$ 18,436.97 | \$ 14,840.25 | \$ 13,257.38 | \$ 12,374.62 |
| 0203 | \$ 20,383.52 | \$ 16,405.50 | \$ 14,657.61 | \$ 13,680.33 |
| 0204 | \$ 22,174.67 | \$ 17,849.00 | \$ 15,945.70 | \$ 14,883.51 |
| 0205 | \$ 26,162.29 | \$ 21,056.40 | \$ 18,813.46 | \$ 17,559.02 |
| 0206 | \$ 31,498.89 | \$ 25,353.23 | \$ 22,652.09 | \$ 21,141.31 |
| 0207 | \$ 39,833.01 | \$ 32,061.23 | \$ 28,643.95 | \$ 26,734.24 |
| 0301 | \$ 18,787.83 | \$ 15,192.71 | \$ 13,943.08 | \$ 13,033.08 |
| 0302 | \$ 22,985.33 | \$ 18,589.17 | \$ 17,059.16 | \$ 15,945.70 |
| 0303 | \$ 26,550.00 | \$ 21,471.34 | \$ 19,705.83 | \$ 18,417.74 |
| 0304 | \$ 33,969.33 | \$ 27,471.21 | \$ 25,212.25 | \$ 23,565.29 |
| 0401 | \$ 16,085.08 | \$ 12,972.20 | \$ 11,999.73 | \$ 10,982.40 |
| 0402 | \$ 23,828.03 | \$ 19,218.79 | \$ 17,776.90 | \$ 16,269.33 |
| 0403 | \$ 37,950.54 | \$ 30,608.12 | \$ 28,313.91 | \$ 25,913.97 |
| 0404 | \$ 64,687.99 | \$ 52,173.99 | \$ 48,263.26 | \$ 44,171.50 |
| 0405 | \$ 57,955.97 | \$ 46,744.47 | \$ 43,239.08 | \$ 39,573.47 |
| 0501 | \$ 14,692.86 | \$ 11,447.00 | \$ 10,581.87 | \$ 9,724.75 |
| 0502 | \$ 19,516.78 | \$ 15,205.53 | \$ 14,056.83 | \$ 12,917.73 |
| 0503 | \$ 24,281.43 | \$ 18,919.20 | \$ 17,488.52 | \$ 16,070.67 |
| 0504 | \$ 27,918.19 | \$ 21,751.71 | \$ 20,107.96 | \$ 18,477.02 |
| 0505 | \$ 31,973.11 | \$ 24,912.66 | \$ 23,028.59 | \$ 21,162.14 |
| 0506 | \$ 43,250.29 | \$ 33,698.57 | \$ 31,149.63 | \$ 28,624.72 |
| 0601 | \$ 17,200.15 | \$ 13,204.51 | \$ 12,214.41 | \$ 11,131.39 |
| 0602 | \$ 22,301.23 | \$ 17,120.04 | \$ 15,835.16 | \$ 14,431.72 |
| 0603 | \$ 27,434.36 | \$ 21,061.21 | \$ 19,479.93 | \$ 17,754.47 |
| 0604 | \$ 35,483.31 | \$ 27,240.51 | \$ 25,196.23 | \$ 22,964.50 |
| 0701 | \$ 16,469.59 | \$ 13,436.81 | \$ 12,733.49 | \$ 11,488.66 |
| 0702 | \$ 20,960.27 | \$ 17,100.82 | \$ 16,205.24 | \$ 14,622.37 |
| 0703 | \$ 24,992.76 | \$ 20,391.53 | \$ 19,324.53 | \$ 17,435.65 |
| 0704 | \$ 31,893.00 | \$ 26,021.31 | \$ 24,659.52 | \$ 22,249.96 |
| 0801 | \$ 13,443.22 | \$ 10,959.97 | \$ 9,908.99 | \$ 9,218.48 |
| 0802 | \$ 17,248.21 | \$ 14,061.63 | \$ 12,714.27 | \$ 11,826.70 |
| 0803 | \$ 22,626.46 | \$ 18,446.58 | \$ 16,677.86 | \$ 15,514.74 |
| 0804 | \$ 20,389.93 | \$ 16,623.39 | \$ 15,029.30 | \$ 13,981.53 |
| 0805 | \$ 24,302.25 | \$ 19,813.17 | \$ 17,913.08 | \$ 16,663.44 |
| 0806 | \$ 29,944.85 | \$ 24,412.80 | \$ 22,072.13 | \$ 20,532.51 |
| 0901 | \$ 16,474.39 | \$ 12,933.75 | \$ 11,985.31 | \$ 11,044.88 |
| 0902 | \$ 20,875.36 | \$ 16,389.48 | \$ 15,186.31 | \$ 13,995.95 |
| 0903 | \$ 26,053.35 | \$ 20,455.61 | \$ 18,954.45 | \$ 17,467.70 |
| 0904 | \$ 32,637.98 | \$ 25,625.59 | \$ 23,744.72 | \$ 21,883.08 |
| 1001 | \$ 17,528.58 | \$ 14,835.45 | \$ 13,178.87 | \$ 12,150.33 |
| 1002 | \$ 22,403.77 | \$ 18,960.85 | \$ 16,842.88 | \$ 15,529.16 |
| 1003 | \$ 32,437.72 | \$ 27,453.59 | \$ 24,387.17 | \$ 22,483.87 |
| 1101 | \$ 21,817.40 | \$ 16,091.49 | \$ 16,091.49 | \$ 14,149.75 |
| 1102 | \$ 30,773.14 | \$ 22,696.95 | \$ 22,696.95 | \$ 19,958.96 |
| 1201 | \$ 17,823.36 | \$ 15,285.64 | \$ 13,954.29 | \$ 12,619.74 |
| 1202 | \$ 22,576.79 | \$ 19,361.38 | \$ 17,674.37 | \$ 15,985.75 |
| 1203 | \$ 27,343.04 | \$ 23,449.94 | \$ 21,405.66 | \$ 19,359.78 |
| 1301 | \$ 17,586.25 | \$ 15,256.80 | \$ 14,247.48 | \$ 13,364.72 |
| 1201 | \$ 17,300.25 | \$ 13,230.60 | \$ 14,247.40 | \$ 13,304.72 |



| СМС | Payment Rate Tier 1 | Payment Rate Tier 2 | Payment Rate Tier 3 | Payment Rate No Comorbidity |
|------|---------------------|---------------------|---------------------|--------------------------------|
| 1302 | \$ 22,998.15 | \$ 19,952.55 | \$ 18,632.42 | \$ 17,477.31 |
| 1303 | \$ 27,775.61 | \$ 24,097.19 | \$ 22,503.10 | \$ 21,107.67 |
| 1401 | \$ 14,780.97 | \$ 12,033.37 | \$ 10,849.42 | \$ 9,777.62 |
| 1402 | \$ 19,832.40 | \$ 16,147.57 | \$ 14,556.68 | \$ 13,119.60 |
| 1403 | \$ 23,634.18 | \$ 19,242.82 | \$ 17,347.54 | \$ 15,634.89 |
| 1404 | \$ 29,768.62 | \$ 24,238.17 | \$ 21,851.04 | \$ 19,693.01 |
| 1501 | \$ 16,253.30 | \$ 14,023.18 | \$ 12,699.85 | \$ 12,169.55 |
| 1502 | \$ 20,779.24 | \$ 17,929.10 | \$ 16,235.68 | \$ 15,557.99 |
| 1503 | \$ 24,657.92 | \$ 21,275.89 | \$ 19,266.85 | \$ 18,462.60 |
| 1504 | \$ 31,072.73 | \$ 26,811.14 | \$ 24,279.83 | \$ 23,265.70 |
| 1601 | \$ 19,422.26 | \$ 14,867.49 | \$ 14,120.91 | \$ 12,743.10 |
| 1602 | \$ 24,609.86 | \$ 18,837.49 | \$ 17,893.85 | \$ 16,147.57 |
| 1603 | \$ 29,858.34 | \$ 22,855.56 | \$ 21,710.06 | \$ 19,590.48 |
| 1701 | \$ 20,546.93 | \$ 15,578.82 | \$ 14,583.92 | \$ 13,130.81 |
| 1702 | \$ 24,848.57 | \$ 18,840.70 | \$ 17,637.52 | \$ 15,880.02 |
| 1703 | \$ 28,993.20 | \$ 21,984.02 | \$ 20,580.58 | \$ 18,528.29 |
| 1704 | \$ 37,003.70 | \$ 28,057.58 | \$ 26,266.43 | \$ 23,648.60 |
| 1801 | \$ 18,079.70 | \$ 16,121.93 | \$ 13,624.26 | \$ 12,725.48 |
| 1802 | \$ 26,657.34 | \$ 23,771.96 | \$ 20,088.73 | \$ 18,763.80 |
| 1803 | \$ 41,886.90 | \$ 37,352.96 | \$ 31,566.18 | \$ 29,483.45 |
| 1901 | \$ 22,429.40 | \$ 16,099.50 | \$ 15,123.82 | \$ 14,572.70 |
| 1902 | \$ 39,493.37 | \$ 28,347.56 | \$ 26,630.11 | \$ 25,660.84 |
| 1903 | \$ 68,360.00 | \$ 49,067.52 | \$ 46,095.62 | \$ 44,418.22 |
| 2001 | \$ 15,529.16 | \$ 12,350.59 | \$ 11,471.04 | \$ 10,413.65 |
| 2002 | \$ 20,181.65 | \$ 16,049.84 | \$ 14,909.14 | \$ 13,534.54 |
| 2003 | \$ 24,806.92 | \$ 19,728.26 | \$ 18,324.82 | \$ 16,636.21 |
| 2004 | \$ 31,615.84 | \$ 25,144.96 | \$ 23,355.41 | \$ 21,202.19 |
| 2101 | \$ 30,560.06 | \$ 24,821.34 | \$ 23,972.22 | \$ 21,096.45 |
| 5001 | | | | \$ 2,561.76 |
| 5101 | | | | \$ 12,078.23 |
| 5102 | | | | \$ 26,423.44 |
| 5103 | | | | \$ 12,962.59 |
| 5104 | | | | \$ 33,876.40 |

Update to Payments for High-Cost Outliers under the IRF PPS for FY 2019 (Page 60)

CMS is updating the outlier threshold amount from \$8,679 for FY 2018 to **\$9,402** for FY 2019 to maintain estimated outlier payments at approximately 3.0 percent of total estimated aggregate IRF payments for FY 2019.

CMS says that based on an analysis of the data used, the agency estimates that IRF outlier payments as a percentage of total estimated payments would be approximately 3.1 percent in FY 2018.

Removal of the FIM™ Instrument and Associated Function Modifiers from the IRF-PAI Beginning with FY 2020 and Proposed Refinements to the Case-Mix Classification System Beginning with FY 2020 (Page 68)

The IRF-PAI currently in use (IRF-PAI version 2.0) was originally developed based on a modified version of the Uniform Data System for medical rehabilitation (UDSmr) patient assessment instrument, commonly referred to as the FIM $^{\text{TM}}$. Item 39 of the IRF-PAI version 2.0 contains 18 of the FIM $^{\text{TM}}$ data



elements and the FIM™ measurement scale that are used to score both motor and cognitive functioning at admission and discharge. The FIM™ data elements and measurement scale are collectively referred to as the FIM™ instrument. Additionally, items 29 through 38 of the IRF-PAI version 2.0 contain Function Modifiers associated with the FIM™ instrument. The FIM™ instrument and associated Function Modifiers are currently used to assign a patient into a CMG for payment purposes under the IRF PPS based on the patient's ability to perform specific activities of daily living and, in some cases, the patient's cognitive ability.

CMS is finalizing its proposal to remove the FIM™ instrument and associated Function Modifiers from the IRF-PAI beginning in FY 2020 that is, for all discharges occurring on or after October 1, 2019.

Refinements to the Case-Mix Classification System Beginning with FY 2020 (Page 72)

CMS is finalizing its proposal to use the Quality Indicator data items to construct the functional status scores for use in the IRF case-mix classification system and to derive the scores for each respective group of the functional status items by calculating the sum of the items that constitute each functional status component.

CMS is finalizing its proposal to utilize CMGs based on the data items from the Quality Indicators section of the IRF-PAI to classify IRF patients for purposes of establishing payment under the IRF PPS beginning with FY 2020.

Based on public comments, CMS is not finalizing the revised CMG definitions as proposed.

Comment

This is a long section covering some 55 pages.

Revisions to Certain IRF Coverage Requirements Beginning with FY 2019 (Page 127)

CMS is finalizing its proposal to modify $\S412.622(a)(3)(iv)$ to provide that the post-admission physician evaluation required under $\S412.622(a)(4)(ii)$ may count as one of the face-to-face physician visits required under $\S412.622(a)(3)(iv)$ beginning with FY 2019, that is, for all IRF discharges beginning on or after October 1, 2018.

CMS is finalizing its proposal to amend §412.622(a)(5)(A) to expressly provide that the rehabilitation physician may lead the interdisciplinary meeting remotely without any additional documentation requirements beginning with FY 2019. CMS notes that this policy in no way precludes IRFs from exercising their own discretion in determining how best to organize their medical staff or implementing a protocol for determining when the rehabilitation physician should lead the interdisciplinary team meeting in person or remotely.

CMS is finalizing its proposal to amend §412.606(a) to remove the admission order documentation requirement beginning with FY 2019. IRFs will continue to meet the requirements at §§482.12(c), 482.24(c), and 412.3.



Updates to the IRF Quality Reporting Program (QRP) (Page 146)

The IRF QRP currently has 18 currently adopted measures, as outlined in the table below.

Quality Measures Currently Adopted for the IRF QRP

| Short Name | Measure Name & Data Source | | | |
|---|--|--|--|--|
| | IRF-PAI | | | |
| Pressure Ulcer | Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678)* | | | |
| Pressure Ulcer/Injury | Changes in Skin Integrity Post-Acute Care: Pressure Ulcer/Injury | | | |
| Patient Influenza Vaccine | Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680) | | | |
| Application of Falls | Application of Percent of Residents Experiencing One or More Falls with Major Injury (Long Stay) (NQF #0674) | | | |
| Application of Functional Assessment | Application of Percent of Long-Term Care Hospital (LTCH) Patients with an Admission and Discharge Functional Assessment and a Care Plan That Addresses Function (NQF #2631) | | | |
| DRR | Drug Regimen Review Conducted With Follow-Up for Identified Issues- Post Acute Care (PAC) Inpatient Rehabilitation Facility (IRF) Quality Reporting Program (QRP) | | | |
| Change in | IRF Functional Outcome Measure: Change in Self-Care Score for Medical | | | |
| Self-Care | Rehabilitation Patients (NQF #2633) | | | |
| Change in | IRF Functional Outcome Measure: Change in Mobility Score for Medical Rehabilitation Patients | | | |
| Mobility | (NQF #2634) | | | |
| Discharge Self-Care Score | IRF Functional Outcome Measure: Discharge Self-Care Score for Medical Rehabilitation Patients (NQF #2635) | | | |
| Discharge | IRF Functional Outcome Measure: Discharge Mobility Score for Medical Rehabilitation Patients | | | |
| Mobility Score | (NQF #2636) | | | |
| | NHSN | | | |
| CAUTI | National Healthcare Safety Network (NHSN) Catheter-Associated Urinary Tract Infection Outcome Measure (NQF #0138) | | | |
| MRSA | National Healthcare Safety Network (NHSN) Facility-wide Inpatient Hospital- onset Methicillin-resistant Staphylococcus aureus (MRSA) Bacteremia Outcome Measure (NQF #1716) | | | |
| CDI | National Healthcare Safety Network (NHSN) Facility-wide Inpatient Hospital- onset Clostridium difficile Infection (CDI) Outcome Measure (NQF #1717) | | | |
| HCP Influenza | Influenza Vaccination Coverage among Healthcare Personnel (NQF #0431) | | | |
| Vaccine | The state of the s | | | |
| | Claims-Based | | | |
| MSPB IRF Medicare Spending Per Beneficiary (MSPB)-Post Acute Care (PAC) PAC IRF QRP | | | | |
| DTC | Discharge to Community- PAC IRF QRP | | | |
| PPR 30 day | Potentially Preventable 30-Day Post-Discharge Readmission Measure for IRF QRP | | | |
| PPR Within Stay | Potentially Preventable Within Stay Readmission Measure for IRFs | | | |
| ¥ Tl | I ha real and with the Charges in Clair Intervity Doct Asyte Care Drangurg Heav/Initial resource | | | |

^{*} The measure will be replaced with the Changes in Skin Integrity Post-Acute Care: Pressure Ulcer/Injury measure, effective October 1, 2018.



Removal of Two IRF QRP Measures

CMS is adopting its proposal, with the FY 2020 IRF QRP, to remove the National Healthcare Safety Network (NHSN) Facility-wide Inpatient Hospital-onset Methicillin-resistant Staphylococcus aureus (MRSA) Bacteremia Outcome Measure (NQF #1716).

CMS is adopting its proposal to remove one measure beginning with the FY 2021 IRF QRP: Percent of Residents or Patients Who Were Assessed and Appropriately Given the Seasonal Influenza Vaccine (Short Stay) (NQF #0680).